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Objective: To compare the outcome of patients undergoing
autologous peripheral blood stem cell transplantation
(PBSCT) conditioned with FluBuTBI or BEAM (BCNU, Etopo-
side, Cytarabine, and Melphalan) at our institution.
Patients and Methods: We conducted a retrospective
analysis of patients (n¼101) who underwent autologous
PBSCT at our institution and were conditioned with BEAM
(n¼63) or FluBuTBI (n¼38) between January 2006 and
December 2012. Recipients were classiﬁed according to
CIBMTR criteria and those conditioned with BEAM were
low risk (n¼17) and intermediate risk (n¼46). Recipients
conditioned with FluBuTBI were low risk (n¼9), interme-
diate risk (n¼25), and high risk (n¼4). Median age of pa-
tients in the BEAM group was 52.3 years compared to 59.6
years for FluBuTBI. At the time of transplantation, 38 of 63
patients who received BEAM were in complete remission
(60%) compared to 19 of 38 patients (50%) for FluBuTBI.
Median time of follow up was 57 months for BEAM and 24
months for FluBuTBI.
FluBuTBI consisted of intravenous (IV) Fludarabine 50mg/
m2/day infused over 1 hour on days -6 through -2, IV
Busulfan 3.2 mg/kg/day on days -5 through -2 (infusion rate
80 mg/kg/hour) and TBI 200 cGy on days -2 and -1. BEAM
regimen consisted of IV BCNU 300 mg/m2 infused over 1 hr
on day -5, Etoposide 200 mg/m2/day over 3 hours on days -5
through -2, Cytarabine 200 mg/m2/day over 1 hour every 12
hours on days -5 through -2, and Melphalan 140 mg/m2over
1 hr on day -1. Diagnoses were Hodgkin’s lymphoma (n¼26),
B-cell lymphoma NOS (n¼3), anaplastic large cell lymphoma
(n¼2), Burkitt’s lymphoma (n¼3), diffuse large B-cell lym-
phoma (n¼ 23), follicular lymphoma (n¼16), mantle cell
lymphoma (n¼22), peripheral T-cell lymphoma (n¼5),
transformed follicular lymphoma (n¼1).
Results: Overall survival at 3 years for patients undergoing
BEAM was 71% and for FluBuTBI 72%. Cumulative incidence
of disease progression or relapse at 3 years for BEAMwas 39%
compared to 32% for the FluBuTBI group. Treatment related
mortality was 3% (n¼2) in the BEAM group and 0% in the
FluBuTBI group. Treatment related MDS/AML occurred in 6%
(n¼4) in the BEAM group compared to 2% (n¼1) in the Flu-
BuTBI group. Grade 3-4 mucositis was seen in 16% (n¼6) in
the FluBuTBI group compared to 4% (n¼3) in the BEAM
group.
Conclusion: Comparison of the two groups showed identical
overall survival at 3 years, but a trend to reduced relapse,
treatment related mortality and secondary MDS/AML, in
patients conditioned with FluBuTBI. This difference was
present despite older and higher risk patients in the FluBuTBI
group. Mucositis was more frequent in the FluBuTBI group.
Conditioning with FluBuTBI is a safe and effective alternative
to BEAM for autologous PBSCT that offers the potential for
further optimization by study of Busulfan pharmacokinetics
and the introduction of targeted radiation.133
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Evaluate the genotoxicity and oxidative status in patients
undergoing autologous HSCT, different moments comparing
pre-and post-transplantation. The study is a prospective
longitudinal in order to investigate the genotoxicity and
oxidative status in adult patients Undergoing autologous
HSCT, accompanied in the service of Hematology, University
Hospital Walter Cantídio (HUWC), and healthy subjects from
January 2013 to August 2013. The study consisted of control
(n ¼ 30) consisted of healthy volunteers, adults, matched by
sex and age with the patients group. Only one sample was
collected from volunteers. Patients (n¼30) with oncohema-
tologic diseases (multiple myeloma, non-Hodgkin lym-
phoma and Hodgkin lymphoma) that meet the basic
conditions to the completion of the service accompanied
HSCT Hematology HUWC. Determine the concentration of
MDA (malondialdehyde), enzyme superoxide dismutase
(SOD) and in the DI (damage index) were performed before
the CR(conditioning regimen) (CR Pre), 24 hours after the CR
(D - 1), 1 day (D +1), 10 days (D +10 ) and 20 ( D +20 ) days
after autologous HSCT. The determination of MDA based on
its reaction with thiobarbituric acid (TBARS) in heparinized
plasma and measuring the activity of superoxide dismutase
(SOD) in erythrocytes were determined by spectrometry and
comet assay, or technique of cell microgel electrophoresis
was used to assess DNA damage. Statistical analysis was
performed using GraphPad Prism. We used the ANOVA test
for comparison of patients groups and controls. The level of
signiﬁcance is 5 % (p < .05). MDA levels in patients Under-
going HSCT between and control (p< .0001) and between
D-1 and other groups (p < .0001). Levels of the antioxidant
enzyme SOD in patients between control and pre CR (p ¼
.0048), control and D- 1 (p < .0001), and between control
and D +20 (p ¼ .0271), between Pre and D +1 CR (p < .0001)
between D-1 and D +1 (p < .0001), D +10 and D+20
(p<.0001). An increase in ID in patient samples compared to
controls. There was a signiﬁcant increase in damage index 24
hours after the conditioning regimen (D-1) (56.63  15.57)
when compared to the control group (4.935  2.038) and at
other times examined. Results support the hypothesis stated
HSCT induces an Increase in oxidative stress either by
increased production of free radicals and by reduction of
antioxidant enzymes with consequent damage of the DNA.134
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